A217330 Stock Overview
Cytogen, Inc., a biotechnology company, develops and sells CTC (circulating tumor cell) enrichment and downstream systems to treat cancer in South Korea.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Cytogen, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩14,750.00 |
52 Week High | ₩20,200.00 |
52 Week Low | ₩10,100.00 |
Beta | 0.64 |
1 Month Change | -1.67% |
3 Month Change | 11.07% |
1 Year Change | -8.39% |
3 Year Change | -24.23% |
5 Year Change | 256.85% |
Change since IPO | 183.65% |
Recent News & Updates
Shareholder Returns
A217330 | KR Biotechs | KR Market | |
---|---|---|---|
7D | 1.0% | 4.1% | 2.1% |
1Y | -8.4% | 20.9% | 13.4% |
Return vs Industry: A217330 underperformed the KR Biotechs industry which returned 20.9% over the past year.
Return vs Market: A217330 underperformed the KR Market which returned 13.4% over the past year.
Price Volatility
A217330 volatility | |
---|---|
A217330 Average Weekly Movement | 8.9% |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 5.2% |
10% most volatile stocks in KR Market | 12.0% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A217330's share price has been volatile over the past 3 months.
Volatility Over Time: A217330's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 45 | Byung-Hee Jeon | https://www.cytogenlab.com |
Cytogen, Inc., a biotechnology company, develops and sells CTC (circulating tumor cell) enrichment and downstream systems to treat cancer in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immune florescence staining systems; and cell image analyzers, which help capture and analyze multi-fluorescence images with multi-channel image sensors and cameras. It also provides time laps incubators, which help monitoring cell growth and capture cell images from the cell culture plates.
Cytogen, Inc. Fundamentals Summary
A217330 fundamental statistics | |
---|---|
Market cap | ₩328.74b |
Earnings (TTM) | -₩16.40b |
Revenue (TTM) | ₩2.84b |
115.8x
P/S Ratio-20.0x
P/E RatioIs A217330 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A217330 income statement (TTM) | |
---|---|
Revenue | ₩2.84b |
Cost of Revenue | ₩1.95b |
Gross Profit | ₩890.94m |
Other Expenses | ₩17.29b |
Earnings | -₩16.40b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -735.88 |
Gross Margin | 31.39% |
Net Profit Margin | -577.81% |
Debt/Equity Ratio | 96.3% |
How did A217330 perform over the long term?
See historical performance and comparison